Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease

Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease

(2018) Amy Hemperly et al.   CLINICAL PHARMACOKINETICS

Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System

(2018) Alexander Eser et al.   JOURNAL OF CLINICAL PHARMACOLOGY

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial

(2017) Thomas Van Stappen et al.   GUT

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

(2017) Johannan F. Brandse et al.   INFLAMMATORY BOWEL DISEASES

Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease

(2017) Laura Merras-Salmio et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease

(2017) Adam Frymoyer et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease

(2017) Tatyana Hofmekler et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®

(2016) Joseph C. Marini et al.   AAPS Journal

Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients

(2016) Marla C. Dubinsky et al.   AAPS Journal

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease

(2016) Clare Moore et al.   Journal of Crohns & Colitis

Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease

(2016) Adam Frymoyer et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

(2015) David Drobne et al.   Clinical Gastroenterology and Hepatology

Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?

(2015) DR Mould   CLINICAL PHARMACOLOGY & THERAPEUTICS

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside

(2014) Diane R. Mould et al.   AAPS Journal

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

(2014) Niels Vande Casteele et al.   GUT

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease

(2014) Namita Singh et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis

(2013) Eytan Wine et al.   Journal of Crohns & Colitis

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension

(2011) Jeffrey Hyams et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-term outcome of treatment with infliximab in pediatric-onset Crohnʼs disease: A population-based study

(2011) Valérie Crombé et al.   INFLAMMATORY BOWEL DISEASES

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT